TakkonTBI ℞++ VS. Traumatic Brain Damage
TakkonTBI ℞++ is an in-trial organic plant-based neurogenesis medication scheduled for FDA-approval during Winter quarter of 2024. TakkonTBI ℞++ promotes post-traumatic neurogenesis and aids in the recovery of TPC, TFC, RNS, LOX, ROS, AChE, and BChE symptoms.